Literature DB >> 34315957

Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients.

Maria Clara Saad Menezes1, Alicia Dudy Müller Veiga2, Thais Martins de Lima2, Suely Kunimi Kubo Ariga2, Hermes Vieira Barbeiro2, Claudia de Lucena Moreira2, Agnes Araujo Sardinha Pinto2, Rodrigo Antonio Brandao2, Julio Flavio Marchini2, Julio Cesar Alencar2, Lucas Oliveira Marino2, Luz Marina Gomez2, Niels Olsen Saraiva Camara3, Heraldo P Souza2.   

Abstract

The role of innate immunity in COVID-19 is not completely understood. Therefore, this study explored the impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the expression of Pattern Recognition Receptors (PRRs) in peripheral blood cells and their correlated cytokines. Seventy-nine patients with severe COVID-19 on admission, according to World Health Organization (WHO) classification, were divided into two groups: patients who needed mechanical ventilation and/or deceased (SEVERE, n = 50) and patients who used supplementary oxygen but not mechanical ventilation and survived (MILD, n = 29); a control group (CONTROL, n = 17) was also enrolled. In the peripheral blood, gene expression (mRNA) of Toll-like receptors (TLRs) 3, 4, 7, 8, and 9, retinoic-acid inducible gene I (RIGI), NOD-like receptor family pyrin domain containing 3 (NLRP3), interferon alpha (IFN-α), interferon beta (IFN-β), interferon gamma (IFN-γ), interferon lambda (IFN-λ), pro-interleukin(IL)-1β (pro-IL-1β), and IL-18 was determined on admission, between 5-9 days, and between 10-15 days. Circulating cytokines in plasma were also measured. When compared to the COVID-19 MILD group, the COVID-19 SEVERE group had lower expression of TLR3 and overexpression of TLR4.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34315957     DOI: 10.1038/s41598-021-94624-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  7 in total

1.  A genome-wide transcriptomic analysis of protein-coding genes in human blood cells.

Authors:  Mathias Uhlen; Max J Karlsson; Wen Zhong; Abdellah Tebani; Christian Pou; Jaromir Mikes; Tadepally Lakshmikanth; Björn Forsström; Fredrik Edfors; Jacob Odeberg; Adil Mardinoglu; Cheng Zhang; Kalle von Feilitzen; Jan Mulder; Evelina Sjöstedt; Andreas Hober; Per Oksvold; Martin Zwahlen; Fredrik Ponten; Cecilia Lindskog; Åsa Sivertsson; Linn Fagerberg; Petter Brodin
Journal:  Science       Date:  2019-12-20       Impact factor: 47.728

2.  An inflammatory cytokine signature predicts COVID-19 severity and survival.

Authors:  Diane Marie Del Valle; Seunghee Kim-Schulze; Hsin-Hui Huang; Noam D Beckmann; Sharon Nirenberg; Bo Wang; Yonit Lavin; Talia H Swartz; Deepu Madduri; Aryeh Stock; Thomas U Marron; Hui Xie; Manishkumar Patel; Kevin Tuballes; Oliver Van Oekelen; Adeeb Rahman; Patricia Kovatch; Judith A Aberg; Eric Schadt; Sundar Jagannath; Madhu Mazumdar; Alexander W Charney; Adolfo Firpo-Betancourt; Damodara Rao Mendu; Jeffrey Jhang; David Reich; Keith Sigel; Carlos Cordon-Cardo; Marc Feldmann; Samir Parekh; Miriam Merad; Sacha Gnjatic
Journal:  Nat Med       Date:  2020-08-24       Impact factor: 53.440

3.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Allison L Totura; Alan Whitmore; Sudhakar Agnihothram; Alexandra Schäfer; Michael G Katze; Mark T Heise; Ralph S Baric
Journal:  mBio       Date:  2015-05-26       Impact factor: 7.867

4.  Questions concerning the proximal origin of SARS-CoV-2.

Authors:  Murat Seyran; Damiano Pizzol; Parise Adadi; Tarek M A El-Aziz; Sk Sarif Hassan; Antonio Soares; Ramesh Kandimalla; Kenneth Lundstrom; Murtaza Tambuwala; Alaa A A Aljabali; Amos Lal; Gajendra K Azad; Pabitra P Choudhury; Vladimir N Uversky; Samendra P Sherchan; Bruce D Uhal; Nima Rezaei; Adam M Brufsky
Journal:  J Med Virol       Date:  2020-09-03       Impact factor: 2.327

5.  Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2.

Authors:  Paul Bastard; Romain Lévy; Soledad Henriquez; Christine Bodemer; Tali-Anne Szwebel; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2021-03-25       Impact factor: 8.317

6.  Effect of Positive End-Expiratory Pressure and Proning on Ventilation and Perfusion in COVID-19 Acute Respiratory Distress Syndrome.

Authors:  François Perier; Samuel Tuffet; Tommaso Maraffi; Glasiele Alcala; Marcus Victor; Anne-Fleur Haudebourg; Nicolas De Prost; Marcelo Amato; Guillaume Carteaux; Armand Mekontso Dessap
Journal:  Am J Respir Crit Care Med       Date:  2020-12-15       Impact factor: 21.405

7.  COVID-19 hospital admissions: Brazil's first and second waves compared.

Authors:  Leonardo Sl Bastos; Otavio T Ranzani; Thiago Moreno L Souza; Silvio Hamacher; Fernando A Bozza
Journal:  Lancet Respir Med       Date:  2021-07-15       Impact factor: 30.700

  7 in total
  4 in total

1.  The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.

Authors:  Shima Makaremi; Ali Asgarzadeh; Hamed Kianfar; Alireza Mohammadnia; Vahid Asghariazar; Elham Safarzadeh
Journal:  Inflamm Res       Date:  2022-06-25       Impact factor: 6.986

2.  Off-target effects of bacillus Calmette-Guérin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19.

Authors:  Nicole L Messina; Susie Germano; Rebecca McElroy; Rajeev Rudraraju; Rhian Bonnici; Laure F Pittet; Melanie R Neeland; Suellen Nicholson; Kanta Subbarao; Nigel Curtis
Journal:  Clin Transl Immunology       Date:  2022-04-22

Review 3.  Host cell-intrinsic innate immune recognition of SARS-CoV-2.

Authors:  Emily A Madden; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2021-11-11       Impact factor: 7.090

4.  Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.

Authors:  Ching-Fen Shen; Chia-Liang Yen; Yi-Chen Fu; Chao-Min Cheng; Tzu-Chi Shen; Pei-De Chang; Kuang-Hsiung Cheng; Ching-Chuan Liu; Yu-Tzu Chang; Po-Lin Chen; Wen-Chien Ko; Chi-Chang Shieh
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.